Related Experiment Video
Updated: Jun 30, 2025
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
Immunoembolization for the Treatment of Uveal Melanoma Hepatic Metastases
1Interventional Radiology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Abstract:
Uveal melanoma is the most common primary intraocular tumor in adults. Approximately 50% of patients develop metastatic disease despite successful treatment of the primary eye tumor. The liver is the most common site of metastatic disease occurring in more than 90% of patients. Clinical prognosis is dependent on the ability to control the growth of liver tumors. Locoregional therapies play an important role in stabilizing liver metastases, prolonging survival for patients with metastatic uveal melanoma. As overall survival is prolonged, the development of extrahepatic disease becomes more common. Immunoembolization, a form of liver-directed therapy, not only focuses on treating hepatic metastases by stimulating the local immune system to suppress the growth of liver tumors, but it potentially generates a systemic immune response delaying the growth of extrahepatic metastases as well. The following article discusses immunoembolization for the treatment of metastatic uveal melanoma including the rationale, mechanism of action, indications, contraindications, outcomes, and associated toxicities.
Insights
Immunoembolization offers a novel approach to treating uveal melanoma liver metastases by stimulating the immune system. This liver-directed therapy may also help delay the spread of cancer to other organs.
Area of Science:
- Oncology
- Immunology
- Ophthalmology
Background:
- Uveal melanoma is the most common primary adult intraocular tumor.
- Metastatic disease affects 50% of patients, primarily in the liver (over 90%).
- Controlling liver tumor growth is crucial for patient prognosis.
Purpose of the Study:
- To discuss immunoembolization for metastatic uveal melanoma.
- To explore the rationale, mechanism, and outcomes of this therapy.
- To review indications, contraindications, and toxicities.
Main Methods:
- Immunoembolization as a liver-directed therapy.
- Stimulation of the local immune system to suppress liver tumors.
- Potential generation of a systemic immune response.
Main Results:
- Locoregional therapies stabilize liver metastases and prolong survival.
- Prolonged survival increases the risk of extrahepatic disease.
- Immunoembolization treats hepatic metastases and may delay extrahepatic spread.
Conclusions:
- Immunoembolization is a promising treatment for metastatic uveal melanoma.
- The therapy targets liver metastases and potentially offers systemic benefits.
- Further understanding of its outcomes and toxicities is essential.
